Rege Nephro Co., Ltd.
- Medical Engineering & Biotechnology
Corporate Number｜9130001065343
Rege Nephro is a biotech company developing cell therapy for chronic kidney disease (CKD) and founded in 2019.
There are 13 million patients with CKD in Japan, of which 340,000 are severe CKD patients forced to undergo artificial dialysis. The healthcare cost of dialysis is $12 billion, 4% of the total healthcare cost of Japan.
However, there is still no curative treatment for CKD. Rege Nephro tries to treat patients suffering from CKD with cell therapy using nephron progenitor cells differentiated from iPS cells.
